Trial Profile

A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Respiratory syncytial virus vaccine Pfizer (Primary)
Indications Respiratory syncytial virus infections
Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
Acronyms RENOIR
Sponsors Pfizer

Most Recent Events

28 Jan 2026 Planned End Date changed from 9 Jan 2027 to 18 Jan 2027.
28 Jan 2026 Planned primary completion date changed from 9 Jan 2027 to 18 Jan 2027.
17 Sep 2025 The protocol has been amended to addition in safety endpoints.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com